Radiation-induced lung injury: from mechanism to prognosis and drug therapy

Radiation Oncology

Table 2 Summary of pharmacotherapy for RILI

Drugs	Targets	Inhibition of pneumonia	Inhibition of fibrosis	Effects on anti-tumor	Research type	References
Pulmozyme	cGAS/ STING/ NLRP3 pathway	Yes	Yes	Undetected	Preclinical study	Zhang et al. [93]
Pirfenidone	M2; TGF-β1/Smad3 pathway	Undetected	Yes	Undetected	Preclinical study	Ying et al. [94]
MSC-EVs	VECs; ATM/P53/P21 pathway	Yes	Yes	Undetected	Preclinical study	Lei et al. [95]
IR-780	Fibroblasts; Macrophages	Yes	Yes	Positive	Preclinical study	Luo et al. [96]
2-ME	HIF-1α; VECs	Undetected	Yes	Positive	Preclinical study	Nam et al. [97]
Glibenclamide	VECs	Yes	Yes	Undetected	Preclinical study	Xia et al. [98]
Glucosamine	AECs	Yes	Yes	Undetected	Preclinical study	Lei et al. [99]
Isoflavone	NF-κB pathway	Yes	Undetected	Undetected	Preclinical study	Fountain et al. [100]
Thyroid hormone	M2; TGF-β1/Smads pathway	Undetected	Yes	Undetected	Preclinical study	Li et al. [101]
Bintrafusp alfa	Fibroblasts; TGF-β1/Smads pathway	Undetected	Yes	Positive	Preclinical study	Lan et al. [16]
Lovastatin	ROS; HMOX1	Yes	Undetected	Undetected	Preclinical study	Dasgupta et al. [102]
Anisodamine	ROS; Nrf2/ARE pathway	Yes	Undetected	Undetected	Preclinical study	Guo et al. [103]
Antioxidant liposome	Macrophages; Neutrophils	Yes	Yes	Undetected	Preclinical study	Zhou et al. [104]
ACT001	NLRP3; ROS	Yes	Yes	Undetected	Preclinical study	Luo et al. [105]

Abbreviation: AECs, alveolar epithelial cells; EVs, extracellular vesicles; HIF, hypoxia inducible factor; HMOX1, heme oxygenase 1; MSC, mesenchymal stem cell; NLRP3, NOD-like receptor thermal protein domain associated protein 3; ROS, reactive oxygen species; TGF-β, transforming growth factor-β

ISSN: 1748-717X